development of psychedelic medicines called psychoplastogensOn August 10, Charles Duncan at Cantor Fitzgerald initiated coverage on Mind Medicine stock with an Overweight rating and a target price of $3. The analyst believes that the drug pipeline of Mind Medicine is underappreciated by investors.